Monthly
US$200
Billed every month
磷酸奥司他韦颗粒
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applicationsNo longer listed under review: 1 applicationSupplement delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders12View records ↓
Under-review filings12View records ↓
This year’s generic filers5View records ↓
NHSA approval numbers12View records ↓
API companies with A status33View records ↓
Chemical-drug catalogue
Loaded records: 12 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 11 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 中山万汉制药有限公司 | 中山万汉制药有限公司 | 国药准字H20266185 | 2026/09/29 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 柏士顿（海南）医疗科技有限公司 | 东莞市金美济药业有限公司 | 国药准字H20265974 | 2026/09/15 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东九瑞科技开发有限公司 | 东莞市金美济药业有限公司 | 国药准字H20265831 | 2026/09/02 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20263650 | 2026/03/17 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南慧泽生物医药科技有限公司 | 湖南嘉恒制药有限公司 | 国药准字H20254848 | 2025/07/15 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北康源药业有限公司 | 湖北中古生物制药有限公司 | 国药准字H20249811 | 2024/12/25 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南天济草堂制药股份有限公司 | 湖南天济草堂制药股份有限公司 | 国药准字H20249791 | 2024/12/25 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | 江西施美药业股份有限公司 | 国药准字H20243826 | 2024/05/28 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 博瑞制药（苏州）有限公司 | 博瑞制药（苏州）有限公司 | 国药准字H20234694 | 2023/12/26 | 0.9g（按 C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中润药业有限公司 | 华益药业科技（安徽）有限公司 | 国药准字H20234026 | 2023/08/08 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南先施药业有限公司 | 湖南九典制药股份有限公司 | 国药准字H20233979 | 2023/08/01 | 0.9g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宜昌东阳光长江药业股份有限公司 | 宜昌东阳光长江药业股份有限公司 | 国药准字H20093721 | 2023/07/31 | 0.9g（按C<sub>16</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 12 distinct approval numbers and 11 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 湖北康源药业有限公司 | 国药准字H20249811 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010101825 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20080763 | 15mg(以奥司他韦计) | Category B (乙) | XJ05AHA218N001010101997 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20263650 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010102013 | NHSA |
| 成都第一制药有限公司 | 国药准字H20253139 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010102020 | NHSA |
| 湖南天济草堂制药股份有限公司 | 国药准字H20249791 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010109604 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20266185 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010109920 | NHSA |
| 江苏欣力元生物制药有限公司 | 国药准字H20234694 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010180081 | NHSA |
| 江苏诺泰澳赛诺生物制药股份有限公司 | 国药准字H20243826 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010180539 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20233979 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010183585 | NHSA |
| 湖南慧泽生物医药科技有限公司 | 国药准字H20254848 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010183916 | NHSA |
| 中润药业有限公司 | 国药准字H20234026 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001010184212 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20080763 | 15mg(以奥司他韦计) | Category B (乙) | XJ05AHA218N001010201997 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20080763 | 15mg(以奥司他韦计) | Category B (乙) | XJ05AHA218N001010301997 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20093721 | 0.9g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218N001020101997 | NHSA |
| 江苏欣力元生物制药有限公司 | 国药准字H20234694 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001020180081 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20233979 | 0.9g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218N001020183585 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20093721 | 0.9g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218N001030101997 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 12 filings and 12 distinct first applicants.
Generic 11 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江尖峰药业有限公司 | CYHS2601485 | Generic | 2026/06/24 | Not stated by source | CDE |
| 重庆万霖生物医药科技有限公司;湖南九典制药股份有限公司 | CYHS2601380 | Generic | 2026/06/11 | Not stated by source | CDE |
| 宁波美诺华天康药业有限公司 | CYHS2600921 | Generic | 2026/04/22 | Not stated by source | CDE |
| 湖南普道医药技术有限公司;湖南九典制药股份有限公司 | CYHS2600737 | Generic | 2026/03/28 | Not stated by source | CDE |
| 湖南千金湘江药业股份有限公司 | CYHS2504308 | Generic | 2025/12/18 | Not stated by source | CDE |
| 华益药业科技（安徽）有限公司 | CYHS2503675 | Generic | 2025/10/15 | Not stated by source | CDE |
| 山东普瑞曼药业有限公司 | CYHS2503650 | Generic | 2025/10/14 | Not stated by source | CDE |
| 宜昌东阳光长江药业股份有限公司 | CYHB2501952 | Supplement | 2025/09/30 | Not stated by source | CDE |
| 山东朗诺制药有限公司 | CYHS2503199 | Generic | 2025/08/30 | Not stated by source | CDE |
| 湖南欧亚药业有限公司;湖南嘉恒制药有限公司 | CYHS2503065 | Generic | 2025/08/21 | Not stated by source | CDE |
| 江西施美药业股份有限公司 | CYHS2502573 | Generic | 2025/07/17 | Not stated by source | CDE |
| 湖南威特制药股份有限公司 | CYHS2602733 | Generic | 2026/11/09 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 5 filings and 5 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江尖峰药业有限公司 | CYHS2601485 | Generic | 2026/06/24 | Not stated by source | CDE |
| 重庆万霖生物医药科技有限公司;湖南九典制药股份有限公司 | CYHS2601380 | Generic | 2026/06/11 | Not stated by source | CDE |
| 宁波美诺华天康药业有限公司 | CYHS2600921 | Generic | 2026/04/22 | Not stated by source | CDE |
| 湖南普道医药技术有限公司;湖南九典制药股份有限公司 | CYHS2600737 | Generic | 2026/03/28 | Not stated by source | CDE |
| 湖南威特制药股份有限公司 | CYHS2602733 | Generic | 2026/11/09 | Not stated by source | CDE |
API registrations
Non-component matches: 33 companies with A status and 5 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 磷酸奥司他韦 | 白云山东泰商丘药业有限公司 | Y20260000131 | I | Exact ingredient | 2026/03/20 | CDE |
| 磷酸奥司他韦 | 吉林敖东洮南药业股份有限公司 | Y20250001476 | I | Exact ingredient | 2026/01/09 | CDE |
| 磷酸奥司他韦 | 新天地药业股份有限公司 | Y20250001153 | I | Exact ingredient | 2025/11/07 | CDE |
| 磷酸奥司他韦 | 河北华晨药业集团有限公司 | Y20240001127 | A | Exact ingredient | 2026/03/16 | CDE |
| 磷酸奥司他韦 | 新乡双鹭药业有限公司 | Y20240000651 | A | Exact ingredient | 2026/05/07 | CDE |
| 磷酸奥司他韦 | 万洋衡水制药有限公司 | Y20240000564 | A | Exact ingredient | 2026/09/29 | CDE |
| 磷酸奥司他韦 | 珠海海瑞德制药有限公司 | Y20240000421 | A | Exact ingredient | 2026/01/07 | CDE |
| 磷酸奥司他韦 | 深圳市海滨制药有限公司 | Y20240000379 | A | Exact ingredient | 2026/04/01 | CDE |
| 磷酸奥司他韦 | 浙江华海药业股份有限公司 | Y20230000607 | A | Exact ingredient | 2025/02/07 | CDE |
| 磷酸奥司他韦 | 遂成药业股份有限公司 | Y20230000528 | A | Exact ingredient | 2024/09/30 | CDE |
| 磷酸奥司他韦 | 乳源东阳光药业有限公司 | Y20230000225 | A | Exact ingredient | 2025/12/05 | CDE |
| 磷酸奥司他韦 | 福建省福抗药业股份有限公司 | Y20230000154 | A | Exact ingredient | 2025/10/16 | CDE |
| 磷酸奥司他韦 | 北京金城泰尔制药有限公司 | Y20220001282 | A | Exact ingredient | 2025/07/23 | CDE |
| 磷酸奥司他韦 | 遂成药业股份有限公司 | Y20220001053 | I | Exact ingredient | 2023/04/25 | CDE |
| 磷酸奥司他韦 | 苏州正济药业有限公司 | Y20220000844 | A | Exact ingredient | 2025/03/05 | CDE |
| 磷酸奥司他韦 | 浙江普洛康裕制药有限公司 | Y20220000876 | A | Exact ingredient | 2025/07/28 | CDE |
| 磷酸奥司他韦 | 天方药业有限公司 | Y20220000727 | A | Exact ingredient | 2026/05/20 | CDE |
| 磷酸奥司他韦 | 湖南欧亚药业有限公司 | Y20220000508 | A | Exact ingredient | 2025/09/11 | CDE |
| 磷酸奥司他韦 | 海正药业南通有限公司 | Y20220000102 | A | Exact ingredient | 2024/02/28 | CDE |
| 磷酸奥司他韦 | 杭州福斯特药业有限公司 | Y20220000223 | A | Exact ingredient | 2024/05/21 | CDE |
| 磷酸奥司他韦 | 重庆瑞泊莱制药有限公司 | Y20220000017 | A | Exact ingredient | 2025/03/11 | CDE |
| 磷酸奥司他韦 | INIST ST Co., Ltd. | Y20210001077 | A | Exact ingredient | 2024/03/25 | CDE |
| 磷酸奥司他韦 | 重庆圣华曦药业股份有限公司 | Y20210000702 | A | Exact ingredient | 2025/12/17 | CDE |
| 磷酸奥司他韦 | SOLARA ACTIVE PHARMA SCIENCES LIMITED | Y20210000504 | A | Exact ingredient | 2024/02/08 | CDE |
| 磷酸奥司他韦 | Innovare Labs Private Limited | Y20210000432 | A | Exact ingredient | 2023/08/01 | CDE |
| 磷酸奥司他韦 | 湖南九典宏阳制药有限公司 | Y20210000419 | A | Exact ingredient | 2025/01/11 | CDE |
| 磷酸奥司他韦 | 南京海鲸药业股份有限公司 | Y20210000418 | A | Exact ingredient | 2024/03/26 | CDE |
| 磷酸奥司他韦 | 上海迪赛诺化学制药有限公司 | Y20210000082 | A | Exact ingredient | 2024/04/12 | CDE |
| 磷酸奥司他韦 | 中山万汉制药有限公司 | Y20200001194 | A | Exact ingredient | 2024/10/31 | CDE |
| 磷酸奥司他韦 | 杨凌吉泰药业有限公司 | Y20200000789 | A | Exact ingredient | 2023/03/24 | CDE |
| 磷酸奥司他韦 | 江苏诺泰澳赛诺生物制药股份有限公司 | Y20200000736 | A | Exact ingredient | 2026/10/11 | CDE |
| 磷酸奥司他韦 | Matrix Pharmacorp Private Limited | Y20200000772 | A | Exact ingredient | 2026/08/22 | CDE |
| 磷酸奥司他韦 | Laurus Labs Limited | Y20190000837 | A | Exact ingredient | 2024/07/18 | CDE |
| 磷酸奥司他韦 | 宜昌东阳光长江药业股份有限公司 | Y20190009757 | A | Exact ingredient | 2023/03/24 | CDE |
| 磷酸奥司他韦 | 博瑞制药（苏州）有限公司 | Y20180001370 | A | Exact ingredient | 2026/05/08 | CDE |
| 磷酸奥司他韦 | MSN Pharmachem Private Limited | Y20190000398 | A | Exact ingredient | 2026/05/20 | CDE |
| 磷酸奥司他韦 | Raks Pharma Pvt.Ltd. | Y20190000606 | I | Exact ingredient | 2019/08/14 | CDE |
| 磷酸奥司他韦 | Hetero Labs Limited | Y20180001225 | A | Exact ingredient | 2026/10/12 | CDE |
| 磷酸奥司他韦 | 宜昌东阳光长江药业股份有限公司 | Y20170001954 | A | Exact ingredient | 2026/08/07 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/09Accepted
-
2026/10/23No longer listed under review
康普药业股份有限公司;东莞市金美济药业有限公司
CYHB2601790
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2026/09/22
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/21); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 24
NMPA · Table row 24 ↗ View source ↗ -
2026/10/21Supplement delivery
康普药业股份有限公司
CYHB2601790
Fact date: 2026/10/21 · Publication date: 2026/10/23 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 24 ↗ -
2026/09/22Accepted
康普药业股份有限公司;东莞市金美济药业有限公司
CYHB2601790
Fact date: 2026/09/22 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy